Division of Urology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
BJU Int. 2013 Jul;112(1):13-25. doi: 10.1111/j.1464-410X.2012.11762.x. Epub 2013 Jan 29.
WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Bladder preservation therapies for muscle-invasive bladder cancer (MIBC) have been developed to address the needs of two cohorts: patients with severe medical co-morbidities for whom radical cystectomy is too high risk and patients with limited disease who wish to avoid aggressive surgery. There are multiple bladder preservation options, although the trimodal approach of maximal transurethral resection with chemoradiotherapy is the most strongly supported. While outcomes are worse for patients unfit for surgery than those otherwise fit for surgery, bladder preservation approaches still offer curative potential. We present a comprehensive review of the literature and outline a practical approach to bladder preservation therapy for MIBC. This review aims to help urologists easily navigate through the decision tree of therapeutic options. Radical cystectomy (RC) is associated with considerable morbidity. Aside from the perioperative period, RC with urinary diversion poses great potential for long-term complications and morbidity. Bladder preservation therapies for muscle-invasive bladder cancer (MIBC) have been developed to address the needs of two cohorts: patients with severe medical co-morbidities for whom a radical surgery is too high risk and patients with limited disease who wish to avoid radical surgery. The goal of achieving complete response to treatment while maintaining bladder form and function has led to the development of multimodal approaches to this disease. There are multiple bladder preservation options, although the trimodal approach of maximal transurethral resection with chemoradiotherapy is the most strongly supported. In medically operable patients ('fit' for surgery), there is abundant evidence to support trimodal therapy as an acceptable treatment option for highly selected patients with MIBC with favourable pathological parameters. While outcomes are worse for medically inoperable patients ('unfit' for surgery), bladder preservation approaches still offer curative potential. However, prospective trials comparing the above regimens to RC are still needed to better define their role in the treatment of MIBC. We present a comprehensive review of the literature and outline a practical approach to bladder preservation therapy for MIBC.
主题已知内容是什么?以及这项研究增加了什么内容?:为满足两组患者的需求,已经开发出了用于肌层浸润性膀胱癌(MIBC)的膀胱保留疗法:一组是因为严重合并症而不适合接受根治性膀胱切除术的患者,另一组是希望避免激进手术的疾病有限的患者。有多种膀胱保留选择,尽管最大限度经尿道切除术联合放化疗的三联疗法是最受支持的。对于不适合手术的患者,其结果比其他适合手术的患者更差,但膀胱保留方法仍具有治愈潜力。我们对文献进行了全面回顾,并概述了 MIBC 的膀胱保留治疗的实用方法。本综述旨在帮助泌尿科医生轻松地在治疗方案的决策树中进行导航。根治性膀胱切除术(RC)与相当大的发病率有关。除了围手术期外,RC 伴尿路改道也存在长期并发症和发病率高的潜在风险。为满足两组患者的需求,已经开发出了用于肌层浸润性膀胱癌(MIBC)的膀胱保留疗法:一组是因为严重合并症而不适合接受根治性膀胱切除术的患者,另一组是希望避免激进手术的疾病有限的患者。实现完全缓解治疗的同时保持膀胱形态和功能的目标,导致了针对这种疾病的多模式方法的发展。有多种膀胱保留选择,尽管最大限度经尿道切除术联合放化疗的三联疗法是最受支持的。在有手术治疗能力的患者(“适合”手术)中,有大量证据支持对 MIBC 中具有有利病理参数的高度选择患者采用三联疗法作为一种可接受的治疗选择。对于没有手术治疗能力的患者(“不适合”手术),膀胱保留方法仍具有治愈潜力。然而,仍需要前瞻性试验来比较上述方案与 RC,以更好地确定它们在 MIBC 治疗中的作用。我们对文献进行了全面回顾,并概述了 MIBC 的膀胱保留治疗的实用方法。